Azilsartan Suppresses Osteoclastogenesis and Ameliorates Ovariectomy-Induced Osteoporosis by Inhibiting Reactive Oxygen Species Production and Activating Nrf2 Signaling

Abstract

Osteoporosis is characterized by a decrease in bone mass and destruction of the bone microarchitecture, and it commonly occurs in postmenopausal women and the elderly. Overactivation of osteoclasts caused by the inflammatory response or oxidative stress leads to osteoporosis. An increasing number of studies have suggested that intracellular reactive oxygen species (ROS) are strongly associated with osteoclastogenesis. As a novel angiotensin (Ang) II receptor blocker (ARB), azilsartan was reported to be associated with the inhibition of intracellular oxidative stress processes. However, the relationship between azilsartan and osteoclastogenesis is still unknown. In this study, we explored the effect of azilsartan on ovariectomy-induced osteoporosis in mice. Azilsartan significantly inhibited the receptor activator of nuclear factor-κB ligand (RANKL)-mediated osteoclastogenesis and downregulated the expression of osteoclast-associated markers (Nfatc1, c-Fos, and Ctsk) in vitro. Furthermore, azilsartan reduced RANKL-induced ROS production by increasing the expression of nuclear factor erythroid 2-related factor 2 (Nrf2). Mechanistically, azilsartan inhibited the activation of MAPK/NF-κB signaling pathways, while Nrf2 silencing reversed the inhibitory effect of azilsartan on MAPK/NF-κB signaling pathways. Consistent with the in vitro data, azilsartan administration ameliorated ovariectomy (OVX)-induced osteoporosis, and decreased ROS levels in vivo. In conclusion, azilsartan inhibited oxidative stress and may be a novel treatment strategy for osteoporosis caused by osteoclast overactivation.

The protective effects of Azilsartan against hypoxia in endometrial stromal cells: an implication in endometriosis

“…Rats in the sham group were subjected to a similar surgery without transplantation of the uterine tissue. Rats in the EMS group were randomly divided into 2 groups: in the EMS model group, rats were orally treated with an equal volume of normal saline solution; in the AZL treatment group, rats were orally treated with AZL (3.0 mg/kg body weight) [11] for 21 days after surgery.…”

RETRACTED: Trehalose improves palmitic acid‐induced apoptosis of osteoblasts by regulating SIRT3‐medicated autophagy via the AMPK/mTOR/ULK1 pathway

“…Osteoporosis is a common disease characterized by the disturbance of bone homeostasis, which mainly threatens the health of postmenopausal women and the elderly. 1 At present, the main treatment means are oral drugs to delay the progression of bone loss, but the effect is relatively limited. 2,3 As the pathogenesis of osteoporosis is little known, there is an absence of acceptable grounds for drug design.…”

Corynoline Suppresses Osteoclastogenesis and Attenuates ROS Activities by Regulating NF-κB/MAPKs and Nrf2 Signaling Pathways

“…This leads to reduced levels of antioxidant enzymes and contributes to bone resorption and osteoclast differentiation. Lowering the levels of ROS produced inside the cells can prevent OCG. , Nrf2 lowers ROS levels by inducing the expression of antioxidant enzymes (HO-1, NQO1, and Catalase). Nrf2 belongs to the class of leucine-zooploop-type eukaryotic transcription factors.…”